The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Neurological Disorder Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
The global Neurological Disorder Drugs market size is expected to reach US$ 24800 million by 2029, growing at a CAGR of 3.6% from 2023 to 2029. The market is mainly driven by the significant applications of Neurological Disorder Drugs in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Neurological Disorder Drugs market. Antipsychotic, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hypnotic & Sedative segment is estimated at % CAGR for the next seven-year period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neurological Disorder Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neurological Disorder Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neurological Disorder Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neurological Disorder Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neurological Disorder Drugs covered in this report include Novartis, GlaxoSmithKline, Merck & Co., Bayer, AstraZeneca, Boehringer Ingelheim and Teva Pharmaceutical, etc.
The global Neurological Disorder Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Global Neurological Disorder Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neurological Disorder Drugs market, Segment by Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Global Neurological Disorder Drugs market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neurological Disorder Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Several government initiatives across various countries to educate masses about the rise of various diseases and increasing healthcare sector producing new drugs are the prime reasons for growth of neurological disorder drugs market. European Parkinson’s Disease Association, in Europe is actively supporting research and development by campaigning to raise awareness, and providing medication to patients is boosting the overall neurological disorder drugs market. This region is also witnessing rising focus on research and development programs that will help in producing affordable and effective drugs. The countries are collectively spending on developing neurological disorder drugs thus, improving the revenue of the market during the forecast period.
The global Neurological Disorder Drugs market size is expected to reach US$ 24800 million by 2029, growing at a CAGR of 3.6% from 2023 to 2029. The market is mainly driven by the significant applications of Neurological Disorder Drugs in various end use industries. The expanding demands from the Hospital and Clinic, are propelling Neurological Disorder Drugs market. Antipsychotic, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hypnotic & Sedative segment is estimated at % CAGR for the next seven-year period.
Staggering increase in brain altering disorders such as Alzheimer’s, epilepsy, Parkinson’s, cerebrovascular, and sclerosis are promoting the pharmaceutical firms to tap into the significantly growing neurological disorder drugs market. This will potentially supplement the market growth in the coming years. Rise of several innovative drugs to manage these diseases will swell up the investments in the market. Increasing number of clinical trials are another reason boosting the market. Rise in geriatric population along with patients with strokes, migraines, and headaches leading to cerebrovascular diseases are likely to augment the growth of the market.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Neurological Disorder Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Neurological Disorder Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Neurological Disorder Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Neurological Disorder Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Neurological Disorder Drugs covered in this report include Novartis, GlaxoSmithKline, Merck & Co., Bayer, AstraZeneca, Boehringer Ingelheim and Teva Pharmaceutical, etc.
The global Neurological Disorder Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Novartis
GlaxoSmithKline
Merck & Co.
Bayer
AstraZeneca
Boehringer Ingelheim
Teva Pharmaceutical
Global Neurological Disorder Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Neurological Disorder Drugs market, Segment by Type:
Antipsychotic
Hypnotic & Sedative
Analgesics
Anticoagulants
Others
Global Neurological Disorder Drugs market, by Application
Hospital
Clinic
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Neurological Disorder Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Neurological Disorder Drugs
1.1 Neurological Disorder Drugs Market Overview
1.1.1 Neurological Disorder Drugs Product Scope
1.1.2 Neurological Disorder Drugs Market Status and Outlook
1.2 Global Neurological Disorder Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Neurological Disorder Drugs Market Size by Region (2018-2029)
1.4 Global Neurological Disorder Drugs Historic Market Size by Region (2018-2023)
1.5 Global Neurological Disorder Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Neurological Disorder Drugs Market Size (2018-2029)
1.6.1 North America Neurological Disorder Drugs Market Size (2018-2029)
1.6.2 Europe Neurological Disorder Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Neurological Disorder Drugs Market Size (2018-2029)
1.6.4 Latin America Neurological Disorder Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Neurological Disorder Drugs Market Size (2018-2029)
2 Neurological Disorder Drugs Market by Type
2.1 Introduction
2.1.1 Antipsychotic
2.1.2 Hypnotic & Sedative
2.1.3 Analgesics
2.1.4 Anticoagulants
2.1.5 Others
2.2 Global Neurological Disorder Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Neurological Disorder Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Neurological Disorder Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Neurological Disorder Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Neurological Disorder Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Neurological Disorder Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Neurological Disorder Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Neurological Disorder Drugs Revenue Breakdown by Type (2018-2029)
3 Neurological Disorder Drugs Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.2 Global Neurological Disorder Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Neurological Disorder Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Neurological Disorder Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Neurological Disorder Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Neurological Disorder Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Neurological Disorder Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Neurological Disorder Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Neurological Disorder Drugs Revenue Breakdown by Application (2018-2029)
4 Neurological Disorder Drugs Competition Analysis by Players
4.1 Global Neurological Disorder Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Neurological Disorder Drugs as of 2022)
4.3 Date of Key Players Enter into Neurological Disorder Drugs Market
4.4 Global Top Players Neurological Disorder Drugs Headquarters and Area Served
4.5 Key Players Neurological Disorder Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Neurological Disorder Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Novartis
5.1.1 Novartis Profile
5.1.2 Novartis Main Business
5.1.3 Novartis Neurological Disorder Drugs Products, Services and Solutions
5.1.4 Novartis Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Novartis Recent Developments
5.2 GlaxoSmithKline
5.2.1 GlaxoSmithKline Profile
5.2.2 GlaxoSmithKline Main Business
5.2.3 GlaxoSmithKline Neurological Disorder Drugs Products, Services and Solutions
5.2.4 GlaxoSmithKline Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 GlaxoSmithKline Recent Developments
5.3 Merck & Co.
5.3.1 Merck & Co. Profile
5.3.2 Merck & Co. Main Business
5.3.3 Merck & Co. Neurological Disorder Drugs Products, Services and Solutions
5.3.4 Merck & Co. Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Bayer Recent Developments
5.4 Bayer
5.4.1 Bayer Profile
5.4.2 Bayer Main Business
5.4.3 Bayer Neurological Disorder Drugs Products, Services and Solutions
5.4.4 Bayer Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Bayer Recent Developments
5.5 AstraZeneca
5.5.1 AstraZeneca Profile
5.5.2 AstraZeneca Main Business
5.5.3 AstraZeneca Neurological Disorder Drugs Products, Services and Solutions
5.5.4 AstraZeneca Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 AstraZeneca Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Neurological Disorder Drugs Products, Services and Solutions
5.6.4 Boehringer Ingelheim Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Teva Pharmaceutical
5.7.1 Teva Pharmaceutical Profile
5.7.2 Teva Pharmaceutical Main Business
5.7.3 Teva Pharmaceutical Neurological Disorder Drugs Products, Services and Solutions
5.7.4 Teva Pharmaceutical Neurological Disorder Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Teva Pharmaceutical Recent Developments
6 North America
6.1 North America Neurological Disorder Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Neurological Disorder Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Neurological Disorder Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Neurological Disorder Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Neurological Disorder Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Neurological Disorder Drugs Market Dynamics
11.1 Neurological Disorder Drugs Industry Trends
11.2 Neurological Disorder Drugs Market Drivers
11.3 Neurological Disorder Drugs Market Challenges
11.4 Neurological Disorder Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
